| SC 13G/A | 2020-02-14 | Nussbaum Ran | Enlivex Therapeutics Ltd. | 46,753 | 0.5% | EDGAR |
| SC 13G/A | 2019-09-09 | Hobi Michael | Enlivex Therapeutics Ltd. | 498,432 | 4.9% | EDGAR |
| SC 13G | 2019-06-27 | HBL- HADASIT BIO-HOLDINGS LTD. | Enlivex Therapeutics Ltd. | 1,798,727 | 17.8% | EDGAR |
| SC 13G | 2019-06-26 | KIP Global Pharma-Ecosystem Private Equity Fund | Enlivex Therapeutics Ltd. | 1,417,950 | 14.0% | EDGAR |
| SC 13G | 2019-06-26 | Kretzmer & Associates PLLC | Enlivex Therapeutics Ltd. | 830,973 | 8.2% | EDGAR |
| SC 13G | 2019-06-19 | Hobi Michael | Enlivex Therapeutics Ltd. | 691,310 | 6.8% | EDGAR |
| SC 13D | 2019-05-31 | NOVIK SHAI A | Enlivex Therapeutics Ltd. | 882,515 | 8.6% | EDGAR |
| SC 13G/A | 2019-02-14 | Gilboa Udi | Bioblast Pharma Ltd. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2019-02-14 | Nussbaum Ran | Bioblast Pharma Ltd. | 344,820 | 10.2% | EDGAR |
| SC 13G/A | 2018-02-14 | Nussbaum Ran | Bioblast Pharma Ltd. | 508,052 | 15.2% | EDGAR |
| SC 13G/A | 2018-02-14 | Gilboa Udi | Bioblast Pharma Ltd. | 468,700 | 14.0% | EDGAR |
| SC 13G/A | 2017-02-14 | Visium Asset Management, LP | Bioblast Pharma Ltd. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2017-01-10 | SABBY MANAGEMENT, LLC | Bioblast Pharma Ltd. | 667,662 | 4.1% | EDGAR |
| SC 13G | 2016-03-23 | SABBY MANAGEMENT, LLC | BIO BLAST PHARMA LTD. | 1,011,130 | 6.2% | EDGAR |
| SC 13G/A | 2016-02-12 | Visium Asset Management, LP | BIO BLAST PHARMA LTD. | 844,000 | 5.9% | EDGAR |
| SC 13G | 2015-02-17 | Gilboa Udi | BIO BLAST PHARMA LTD. | 3,320,512 | 23.3% | EDGAR |
| SC 13G | 2015-02-17 | Megiddo Dalia | BIO BLAST PHARMA LTD. | 3,311,421 | 23.3% | EDGAR |
| SC 13G | 2015-02-17 | Nussbaum Ran | BIO BLAST PHARMA LTD. | 2,529,008 | 17.8% | EDGAR |
| SC 13G/A | 2015-02-13 | Visium Asset Management, LP | BIO BLAST PHARMA LTD. | 844,160 | 5.9% | EDGAR |
| SC 13G | 2014-10-17 | Visium Asset Management, LP | BIO BLAST PHARMA LTD. | 777,000 | 5.5% | EDGAR |